Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, India.
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, India.
Eur J Med Chem. 2021 Oct 5;221:113527. doi: 10.1016/j.ejmech.2021.113527. Epub 2021 May 8.
Dengue virus belongs to the class of RNA viruses and subclass of enveloped single-stranded positive-sense RNA virus. It causes dengue fever (DF), dengue hemorrhagic fever (DHF), or dengue shock syndrome (DSS), where DHF and DSS are life-threatening. Even though dengue is an age-old disease, it is still a mystery and continues to be a global threat. Numerous attempts have been carried out in the past few decades to eradicate the virus through vaccine and antiviral drugs, but still battle continues. In this review, the possible drug targets for discovery and development of potential antiviral drugs against structural proteins of dengue virus, the current development status of the antiviral drugs against dengue around the world, and challenges that need to be addressed to overcome the shortcomings in the process of drug discovery have been discussed.
登革病毒属于 RNA 病毒科，为有包膜的单股正链 RNA 病毒亚科。它可引起登革热（DF）、登革出血热（DHF）或登革休克综合征（DSS），其中 DHF 和 DSS 是危及生命的。尽管登革热是一种古老的疾病，但它仍然是一个谜，并且仍然是一个全球性的威胁。在过去的几十年中，人们进行了无数次尝试，通过疫苗和抗病毒药物来消灭这种病毒，但战斗仍在继续。在这篇综述中，讨论了针对登革病毒结构蛋白发现和开发潜在抗病毒药物的可能药物靶点、全球范围内针对登革热的抗病毒药物的当前开发状况，以及克服药物发现过程中的缺点所需要解决的挑战。
